Table 1.
Subject characteristics
| COVID-19 (n = 31) | Flu (n = 29) | Normal (n = 28) | |
|---|---|---|---|
| Age | |||
| Median (range)-years | 50 (23–86) | 59 (27–83) | 37 (22–87) |
| ≤39—No. (%) | 6 (19.35%) | 7 (24.14%) | 14 (50.00%) |
| 40–49—No. (%) | 9 (29.03%) | 5 (17.24%) | 5 (17.86%) |
| 50–59—No. (%) | 9 (29.03%) | 3 (10.34%) | 2 (7.14%) |
| 60–69—No. (%) | 4 (12.90%) | 3 (10.34%) | 5 (17.86%) |
| ≥70—No. (%) | 3 (9.68%) | 11 (37.93%) | 2 (7.14%) |
| Sex | |||
| Female (%) | 14 (45.16%) | 9 (31.03%) | 16 (57.14%) |
| Male (%) | 17 (54.84%) | 20 (68.97%) | 12 (42.86%) |
| Disease severity | |||
| Mild | 2 (6.45%) | ||
| Moderate | 17 (54.84%) | ||
| Severe | 6 (19.35%) | ||
| Critical | 6 (19.35%) | ||
| Blood result median (range) | |||
| Leukocyte count (×109/L, 4.00–10.00) | 5.96 (3.09–20.43) | ||
| Lymphocyte count (×109/L, 0.80–4.00) | 1.05 (0.35–2.96) | ||
| Platelet count (×109/L,100.00–300.00) | 196 (86–456) | ||
| Hemoglobin (g/L, 110–150) | 131 (98–164) | ||
| C-reactive protein (mg/L, 0–8.00) | 12.75 (4.82–200) | ||
| Alanine aminotransferase (U/L, 0–35) | 24 (7–72) | ||
| Lactose dehydrogenase (U/L, 109–245) | 225 (108–1190) | ||
| D-dimer (μg/ml, 0.00–0.50) | 0.49 (0.01–4.05) | ||
| Neutrophil counts (×109/L, 2.00–7.00) | 4 (1.58–19.78) | ||
| AMC (absolute monocyte count, ×109/L, 0.12–1.20) | 0.38 (0.11–0.98) | ||
| NLR (ratio of neutrophils to lymphocyte) | 3.36 (0.82–46) | ||
| PLR (ratio of platelet to lymphocyte) | 200 (59.07–500) | ||
| LMR (ratio of lymphocyte to monocyte) | 2.73 (1.26–6.66) | ||